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Abstract 
 
The human neurotensin 1 receptor (hNTS1) is a G protein-coupled receptor involved in many 
physiological functions, including analgesia, hypothermia, and hypotension. To gain a better 
understanding of which signaling pathways or combination of pathways are linked to NTS1 
activation and function, we investigated the ability of activated hNTS1, which was stably 
expressed by CHO-K1 cells, to directly engage G proteins, activate second messenger cascades 
and recruit β-arrestins. Using BRET-based biosensors, we found that neurotensin (NT), NT(8-13) 
and neuromedin N (NN) activated the Gαq-, Gαi1-, GαoA-, and Gα13-protein signaling pathways as 
well as the recruitment of β-arrestins 1 and 2. Using pharmacological inhibitors, we further 
demonstrated that all three ligands stimulated the production of inositol phosphate and modulation 
of cAMP accumulation along with ERK1/2 activation. Interestingly, despite the functional 
coupling to Gαi1 and GαoA, NT was found to produce higher levels of cAMP in the presence of 
pertussis toxin, supporting that hNTS1 activation leads to cAMP accumulation in a Gαs-dependent 
manner. Additionally, we demonstrated that the full activation of ERK1/2 required signaling 
through both a PTX-sensitive Gi/o-c-Src signaling pathway and PLCb-DAG-PKC-Raf-1-
dependent pathway downstream of Gq. Finally, the whole-cell integrated signatures monitored by 
the cell-based surface plasmon resonance and changes in the electrical impedance of a confluent 
cell monolayer led to identical phenotypic responses between the three ligands. The 
characterization of the hNTS1-mediated cellular signaling network will be helpful to accelerate 
the validation of potential NTS1 biased ligands with an improved therapeutic/adverse effect 
profile. 
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1. Introduction 
 
G protein-coupled receptors (GPCRs) constitute the largest superfamily of cell-surface proteins 
involved in signal transduction (Bockaert, 1999). A large and diverse group of ligands activates 
GPCRs, which transduce intracellular signals by coupling to G proteins or other proteins such as 
arrestins	(Marinissen and Gutkind, 2001). Today, GPCRs are the targets of up to 40% of the total 
drug market and hence continue to be of great interest for the development of therapeutic agents. 
Given that a GPCR can couple to different signaling pathways and that the latter can be selectively 
engaged or blocked led to the emergence of a novel paradigm called bias signaling (Kenakin, 
2013). However, to fully exploit bias signaling, a clear profile of the signaling pathways activated 
by a GPCR is crucial. Here, we focused on deciphering the signaling signature of human NTS1 
following stimulation by endogenous ligands. The neurotensin receptor family is composed of 
three subtypes, NTS1, NTS2, and NTS3	 (Vincent et al., 1999). Among these subtypes, NTS1	
(Tanaka et al., 1990; Vita et al., 1993) and NTS2 (Chalon et al., 1996; Mazella et al., 1996; Vita 
et al., 1998) belong to the rhodopsin-like family of GPCRs, whereas NTS3 belongs to the sortilin 
receptor family	(Mazella and Vincent, 2006; Mazella et al., 1998). Since its discovery, NTS1 has 
been detected in peripheral tissues such as the vascular endothelium and gastrointestinal tract 
(Azriel and Burcher, 2001; Coppola et al., 2008) as well as in the central nervous system (CNS) 
(Roussy et al., 2008), suggesting that it is involved in a broad variety of physiological functions 
(Feng et al., 2015; Osadchii, 2015). Indeed, NTS1 mediates blood pressure lowering (Rioux et al., 
1982), ileum contraction or relaxation (Carraway and Mitra, 1994), analgesia (Roussy et al., 2008), 
and hypothermia (Feifel et al., 2010).  
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NTS1 is endogenously activated by neurotensin (NT) as well as by neuromedin N (NN), both of 
which are derived from the same pro-NT/NN precursor (Rostène and Alexander, 1997; Rovere et 
al., 1996). Structure-activity studies of NT have revealed that the minimal bioactive fragment 
corresponds to the C-terminal hexapeptide of NT, NT(8-13)	(St-Pierre et al., 1981).  
To date, depending on the cell type, NTS1 has been linked, through Gαi/o, Gαq, and Gαs coupling, 
to a variety of intracellular signaling cascades including cyclic AMP (cAMP), inositol phosphate 
(IP), and arachidonic acid accumulation as well as the activation/inhibition of mitogen-activated 
protein kinases (ERK1/2 and JNK) and serine/threonine protein kinase Akt (Müller et al., 2011). 
Interestingly, NTS1-G protein interactions involve different receptor domains; interaction with 
Gαq/11 requires the intact third intracellular loop of the receptor, and coupling to Gαs and Gαi/o 
involves the receptor’s C-terminal domain (Gailly et al., 2000; Grisshammer and Hermans, 2001; 
Najimi et al., 2002; Skrzydelski et al., 2003). NT binding to NTS1 also induces the internalization 
of the receptor–ligand complex via a clathrin-dependent endocytic process requiring the 
recruitment of dynamin, intersectin, and β-arrestins to the GRK2/GRK5 phosphorylated receptor 
(Inagaki et al., 2015; Oakley et al., 2001; 2000; Savdie et al., 2006; Vandenbulcke et al., 2000; 
Zhang, 1999). Like many GPCRs, NTS1 internalization has been shown to lead to G protein-
independent signaling (Souazé et al., 1997; Toy-Miou-Leong et al., 2004). Although the coupling 
to diverse G proteins has been demonstrated through the modulation of second messenger 
cascades, there is still no direct evidence of the interaction between NTS1 and G proteins in a 
unique cell type. 
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In the present study, we used bioluminescence resonance energy transfer (BRET) biosensors and 
label-free whole-cell assays to study the ability of NT, NT(8-13) and NN to activate signaling 
pathways following their binding to hNTS1 expressed in CHO-K1 cells.   
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2. Materials and Methods 
 
2.1 Materials 
Neurotensin 1-13 (NT), IBMX (3-isobutyl-1-methylxantine), SR48692, and forskolin were 
obtained from R&D Systems, Inc. (Minneapolis, MN, USA). NT(8-13) was synthesized at the 
peptide synthesis facility of the Université de Sherbrooke. NN was purchased from GenScript USA 
Inc. (Piscataway, NJ, USA). Coelenterazine 400A (DeepBlueC) was purchased from Gold 
Biotechnology Inc. (St. Louis, MO, USA). The peptide sequences of NT, NT(8-13) and NN are 
shown in Table 1. Ham’s F12, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
Penicillin-streptomycin-glutamine and fetal bovine serum (FBS) were obtained from Wisent (St. 
Bruno, QC, Canada), Opti-MEM was acquired from Invitrogen (Burlington, ON, Canada). Lance 
Ultra cAMP and pERK1/2 assay kits were purchased from Perkin Elmer (Montréal, QC, Canada). 
A Cisbio IP1 assay kit was purchased through Cedarlane (Burlington, ON, Canada). All inhibitors 
used in this study were from Santa-Cruz Biotechnologies (Dallas, TX, USA), with the exception 
of UBOQIC, which was purchased from Bonn University; Pertussis Toxin (PTX) which was 
purchased from List Biological Laboratories (Campbell, CA, USA); Dynasore, which was 
obtained from Tocris (Minneapolis, MN, USA); and Y27632, which was obtained from Cell 
Signaling Technology (Danvers, MA, USA).  
 
2.2 Plasmids and constructs 
The cDNAs encoding the human neurotensin receptor type 1 and the Gβ1 subunit were obtained 
from the Missouri S&T cDNA Resource Center (Rolla, MO, USA). The fusion vector 
pIREShygro3-GFP10 and RlucII-β-arrestin 1 or 2 plasmids were kindly provided by Dr. Michel 
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Bouvier (Dept. of Biochemistry and IRIC, Université de Montréal, Montréal, QC, Canada). Using 
an InFusion advantage PCR cloning kit (Clontech Laboratories, Mountain View, CA, USA), the 
hNTS1 construct was inserted into the pIREShygro3-GFP10 vector as previously described 
(Demeule et al., 2014). The plasmids encoding Gαq-RlucII (Breton et al., 2010), GαoA-RlucII 
(Richard-Lalonde et al., 2013), Gα13-RlucII (Demeule et al., 2014), Gαi1-RlucII, GFP10-Gγ1, and 
GFP10-Gγ2 (Galés et al., 2006) were kindly provided by Dr. Michel Bouvier. All constructs were 
verified by DNA sequencing. 
 
2.3 Cell culture and transfections 
CHO-K1 cells stably expressing hNTS1 (CHO-hNTS1 cells) were purchased from Perkin Elmer 
(Montréal, QC, Canada) and cultured in Ham’s F12 containing 20 mM HEPES, 10% FBS, 0.4 
mg/ml G418, and penicillin (100 U/ml)-streptomycin (100 µg/ml)-glutamine (2 mM) under 5% 
CO2 at 37°C in a humidified atmosphere. The CHO-K1 cells were cultured in the same conditions 
as above but without G418. For the transient expression of recombinant proteins, T75 flasks were 
seeded with 3 × 106 cells, and 24 h later, the cells were transfected using PEI (Ehrhardt et al., 
2006). 
 
2.4 BRET2 assay 
To monitor direct G protein activation, we used the following biosensor couples: Gαq-RlucII, 
GFP10-Gγ1, and Gβ1 (Breton et al., 2010); GαoA-RlucII, GFP10-Gγ1, and Gβ1 (Richard-Lalonde 
et al., 2013); Gα13-RlucII, GFP10-Gγ1, and Gβ1 ; or Gαi1-RlucII, GFP10-Gγ2, and Gβ1 (Galés et 
al., 2006). G protein biosensors were transfected into CHO-hNTS1 cells. At 24 h post-transfection, 
the cells were detached with trypsin-EDTA and plated (50,000 cells/well) in white opaque 96-well 
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plates (BD Falcon, Corning, NY, USA). At 48 h post-transfection, the cells were washed once 
with PBS, and 90 µL of HBSS containing 20 mM HEPES was then added. Ligands were added at 
increasing concentrations for 20 min followed by coelenterazine-400A (5 µM). The BRET2 
measurements were collected in the 400 to 450 nm window (RlucII) and in the 500 to 550 nm 
window (GFP10) using the BRET2 filter set on a GENios Pro plate reader (Tecan, Durham, NC, 
USA). The BRET2 ratio was determined as the light emitted by the acceptor GFP10 over the light 
emitted by the donor RlucII. The monitoring of β-arrestin recruitment was done by the transient 
transfection of CHO-K1 cells with plasmids containing cDNAs encoding hNTS1-GFP10 and 
RlucII-β-arrestin 1 or 2. The same protocol as the one used for G protein activation was then used. 
 
2.5 IP-One and Lance Ultra cAMP assays 
The IP-One assay was performed according to the manufacturer’s recommendations. Briefly, 
15,000 CHO-hNTS1 cells per well (384-well shallow well plate) were treated with increasing 
concentrations of NT, NT (8-13), or NN for 30 min. IP1-d2 and anti-IP1-Cryptate were added for 
at least 1 h. The plates were read on a GENios Pro plate reader with HTRF filters (excitation at 
320 nm and emission at 620 and 665 nm). The TR-FRET ratio was determined as the fluorescence 
of the acceptor (665 nm) over the fluorescence of the donor (620 nm). The Lance Ultra cAMP 
assay was performed according to the manufacturer’s recommendations. Briefly, 1,000 cells per 
well (384-well shallow well plate) were treated with increasing concentrations of NT, NT(8-13), 
or NN for 30 min in the presence or absence of 1 µM forskolin. cAMP-tracer and anti-cAMP-
Cryptate were added for at least 1 h. The plates were read on a GENios Pro plate reader with HTRF 
filters, and the TR-FRET ratio was calculated as described for the IP-One assay. 
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2.6 AlphaScreen assay 
ERK1/2 phosphorylation in the CHO-hNTS1 cells was monitored with Perkin Elmer’s 
AlphaScreen SureFire assays as previously described (Koole et al., 2010). Cells were seeded in 
96-well plates. Twenty-four hours later, the cells were serum-starved overnight. For concentration-
response curves, the cells were stimulated for 10 min with increasing concentrations of NT, NT(8-
13), or NN. For time-course curves, the cells were incubated with inhibitors as mentioned in the 
figure legend and stimulated for 0, 5, 10, 15, 30, 45, and 60 min with 1 µM NT. The cells were 
then lysed with 20 µL of 5X lysis buffer, incubated at room temperature for 10 min on a plate 
shaker, and frozen overnight at -20°C. A total of 5 µL of the lysate was used for analysis. The 
readings were performed on a Perkin Elmer EnSpire 2300 multilabel reader. 
 
2.7 Whole-cell integrated response quantification 
The measurements of the cell monolayer resistivity were performed in cysteine-stabilized, Poly-
L-Lysine-coated 96-well plates (96w20idf from Applied Biophysics, Troy, NY, USA) as 
recommended by the manufacturer. A total of 30,000 CHO-hNTS1 cells were plated into each 
well and allowed to grow for 24 h in serum-containing media before being serum-starved for 16 
to 18 h prior to the experiment. On the day of the experiment, the cells were washed with PBS, 
and 90 µL of Leibovitz's L-15 modification medium (L15; Wisent, St-Bruno, QC, Canada) was 
then added per well. The biophysical parameters (electrical resistance at a 4000 Hz single 
frequency) of the cell monolayer were recorded with an ECIS Zθ linked to a 96-well array station 
(Applied Biophysics, Troy, NY, USA) for 60 min prior to stimulation with NT, NT(8-13) or NN 
at 1, 10, 100 or 1000 nM or in the presence of the NTS1 receptor antagonist SR48692 at 10 µM. 
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The whole-cell integrated behaviors were then monitored for a total of 180 min following 
stimulation.  
Two days before surface plasmon resonance (SPR) detection, the cells were seeded into each well 
containing the SPR substrate (the preparation of the SPR substrate was described by Cuerrier et 
al., (2008) at a density of 100,000 cells/cm² and serum-starved the following day. Before the SPR 
signal was measured, the cells were washed twice with L15 medium and transferred to the SPR 
apparatus. Ninety percent confluency, as evaluated by contrast microscopy, is necessary in order 
to perform the experiment. The SPR analysis was performed at 37°C on a custom-built surface 
plasmon resonance apparatus as previously described (Chabot et al., 2009; Cuerrier et al., 2008). 
 
2.8 Data analysis 
The EC50 values of the BRET2, IP-One, Lance Ultra cAMP, AlphaScreen, and whole-cell 
integrated response assays were determined as the concentration of ligand showing 50% of 
activation. The data were calculated using concentration-response three parameters non-linear 
regression of GraphPad Prism 6 (La Jolla, CA, USA). The experimental numbers are described in 
each figure legend. 
The half-times for β-arrestin recruitment were obtained using the one-phase association 
exponential regression in GraphPad Prism 6 and are represented as the half-time ± S.E.M. of 3 
independent experiments, each done in triplicate. 
Electrical resistivity traces are the averaged normalized response values ± S.E.M. of at least 3 
separate experiments. The normalized response was calculated as the resistivity of the cell 
monolayer divided by the average resistivity during the 60 min baseline. The whole-cell integrated 
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concentration-response curve was generated using the maximum value of the normalized response 
for each ligand concentration.  
SPR traces are the averaged normalized reflectance values ± S.E.M. of at least 6 separate 
experiments. The normalized reflectance was calculated as the reflectance value at a specified time 
minus the reflectance value at the beginning of the experiment. 
Statistical analyses were performed using GraphPad Prism 6 and are described in the figure legend 
when applicable. A value was considered statistically significant when P < 0.05. 
  
This is the accepted (postprint) version of the following article: Besserer-Offroy É, et al. (2017). Eur J 
Pharmacol. doi: 10.1016/j.ejphar.2017.03.046, which has been accepted and published in its final form at 
http://www.sciencedirect.com/science/article/pii/S0014299917302157 	
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 13	
3. Results 
 
3.1 Agonist-dependent hNTS1 activation of Gαq, Gαi, Gαo, and Gα13 
To elucidate the signaling signature of hNTS1 following its binding with NT, NT(8-13), or NN 
(sequences provided in Table 1), we initially assessed the ability of the receptor to couple to 
various G proteins using BRET biosensors in CHO-K1 cells stably expressing the receptor. We 
first determined the ability of hNTS1 to activate Gαq by measuring the dissociation of Gαq-RlucII 
and GFP10-Gγ1. NT, NT(8-13), and NN promoted a decrease in the BRET2 ratio, confirming the 
activation of Gαq by stimulated hNTS1 receptors (Fig. 1A). The activation of Gαq by NT, NT(8-
13), and NN was found to be concentration dependent, and the EC50 values are shown in Table 2. 
These results are in agreement with the potencies previously observed in the NTS1/Gαq-related 
second messenger assays (Choi et al., 1999; Kitabgi et al., 1986). Since several studies have shown 
that NT-induced arachidonic acid production was dependent on the PTX-sensitive Gαi/o pathway 
(Gailly et al., 2000; Najimi et al., 2002), we further investigated whether NTS1 promoted the 
engagement of Gαi1 and GαoA in a similar experimental paradigm as the one used for Gαq (Fig. 1B, 
C; Table 2). Our results show that all three ligands activated both Gαi1 and GαoA. To further study 
the signaling signature of hNTS1, we also assessed the ability of these three ligands to promote 
the activation of Gα13, which is known to modulate small GTPase RhoA activity (Offermanns, 
2003). By measuring the dissociation between Gα13-RlucII and GFP10-Gγ1, we found that NT, 
NT(8-13), and NN promoted the activation of Gα13 (Fig. 1D, Table 2). The concentration-response 
curves revealed dose-dependent activation of Gα13 by NT, NT(8-13), and NN. Altogether, these 
results reveal for the first time the ability of hNTS1 to directly activate the Gαq-, Gαi1-, GαoA-, and 
Gα13-mediated signaling pathways. 
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3.2 Downstream G protein signaling reveals functional coupling with Gαq, Gαs, and Gαi 
To corroborate the results observed with the BRET-based assays, we monitored downstream 
signaling events by quantifying the production of second messengers generated by hNTS1 
activation. For the Gαq pathway, we tested the ability of NT, NT(8-13), and NN to stimulate the 
inositol phosphate (IP) cascade by measuring IP1 accumulation over 30 min (Fig. 2A). 
Interestingly, NT(8-13) was more potent than NT and NN at activating the IP signaling pathway 
(Fig. 2A; Table 2). Moreover, the use of UBOQIC, a Gαq blocker (Inamdar et al., 2015) 
completely abolished the NT-induced increase in inositol phosphate formation (Fig. 2B), thus 
reinforcing the point that NT-induced calcium release is mediated solely through Gαq activation. 
Since NTS1 was found to potentiate the adenylyl cyclase-dependent production of cAMP through 
Gαs activation (Skrzydelski et al., 2003; Yamada et al., 1993), we evaluated the ability of these 
three NTS1 ligands to produce cAMP over a 30-min stimulation period (Fig. 2C). All three ligands 
elevated the cAMP levels, but no differences were observed for the three compounds with respect 
to their EC50 values (Table 2). The production of cAMP is usually related to the activation of Gαs, 
while Gαi/o is known to inhibit cAMP production by adenylyl cyclase. However, there is also 
evidence that NTS1 may trigger a Gαs-independent increase in cAMP levels through Gαq/11-
mediated activation of calcium-dependent adenylyl cyclase (Carraway and Mitra, 1998). In our 
model, we found that the Gαq blocker UBOQIC did not inhibit NT-induced cAMP production, 
therefore reinforcing the role played by Gαs in cAMP accumulation (Fig. 2D). 
To further understand the role of Gαi/o in the cell’s cAMP levels, we next examined the effect of 
blocking Gαi/o function on the NT-induced cAMP accumulation by treating the cells with PTX. 
PTX is a toxin known to interfere on the Gαi/o pathway by an ADP-ribosylation of the Gα subunit 
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resulting in a loss of the ability of this subunit to dissociate from the Gβγ dimer, thus, uncoupling 
the receptor form the Gi/o proteins(Mangmool and Kurose, 2011). Strikingly, NT was found to 
produce higher levels of cAMP in the presence of PTX (Fig. 2D). These results thus suggest that 
hNTS1 is functionally coupled to Gαi/o but that the Gαs-induced cAMP production observed 
following NT treatment counteracts the PTX-sensitive decrease in cAMP formation. 
 
3.3 hNTS1 activation leads to the recruitment of β-arrestins 1 and 2 
Given the predominant role played by β-arrestins in GPCR desensitization and internalization as 
well as G protein-independent signaling (Pierce and Lefkowitz, 2001; Premont and Gainetdinov, 
2007), we further monitored the ability of hNTS1 to recruit β-arrestins 1 and 2 following receptor 
activation. Indeed, it had been previously reported that hNTS1 recruits β-arrestins after NT 
stimulation (Oakley et al., 2001; 2000); however, both the β-arrestin recruitment kinetics and 
potencies were never quantified. We thus used a BRET-based assay to measure the recruitment of 
β-arrestins 1 and 2 to the activated receptor in the CHO-K1 cells expressing hNTS1. We first 
performed time-course experiments to assess the dynamics of β-arrestin recruitment to hNTS1 
(Fig. 3A, B). Our results reveal that NT, NT(8-13) and NN promoted rapid BRET2 increases 
between hNTS1-GFP10 and RlucII-β-arrestin 1 or 2, which indicates β-arrestin recruitment to the 
hNTS1 receptor. For both β-arrestins, the time required for NT, NT(8-13), and NN to reach a 
maximal signal was equivalent, and this maximal response was sustained over time. The 
recruitment of β-arrestin 1 following NT, NT(8-13), or NN stimulation was completed with half 
times of 61.6 ± 5.9 s, 61.5 ± 7.9 s, and 64.9 ± 8.8 s, respectively. β-arrestin 2 recruitment induced 
through NTS1 activation by NT, NT(8-13), or NN was accomplished in half times of 54.8 ± 8.2 s, 
76.5 ± 11.9 s, and 104 ± 20 s, respectively. The recruitment of β-arrestin 1 induced by NTS1 
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activation was found to be concentration-dependent (Fig. 3C), and the EC50 values are summarized 
in Table 2. NT and NT(8-13) were also found to induce β-arrestin 2 recruitment with a higher 
potency than NN (Fig. 3D; Table 2). Given the role of β-arrestins in receptor endocytosis, our 
results on β-arrestin 1 and 2 recruitment suggest that NT, NT(8-13), and NN will lead to hNTS1 
receptor endocytosis (Claing et al., 2002; Ferguson et al., 1996). 
 
3.4 hNTS1 activates ERK1/2 through distinct G protein families 
We next investigated whether NT, NT(8-13), or NN induced the activation of ERK1/2 upon 
hNTS1 stimulation in our cellular model. Therefore, CHO cells stably expressing hNTS1 were 
stimulated with increasing concentrations of NT, NT(8-13), or NN for 10 min prior to the addition 
of lysis buffer. As shown in Fig. 4A, NT, NT(8-13), and NN promoted ERK1/2-phosphorylation 
in a concentration-dependent manner, and the EC50 values are reported in Table 2. Since ERK1/2 
activation can occur through several intracellular mechanisms depending on receptor and cell type, 
we further investigated the contributions of signaling via G protein dependent and independent 
pathways to the activation of the ERK pathway.  
To this end, we used different pharmacological inhibitors to determine which downstream 
signaling pathways mediate the hNTS1 stimulation-induced ERK1/2 phosphorylation. Since 
several studies have reported that GPCRs may mediate ERK1/2 activation through an EGFR 
transactivation-dependent mechanism (Overland and Insel, 2015), we first assessed whether the 
cell-permeable potent selective EGFR inhibitor PD168393 would decrease ERK1/2 
phosphorylation. Our results revealed that EGFR inhibition did not change the ERK1/2 
phosphorylation profile when compared to untreated cells, thereby suggesting that EGFR 
transactivation is not involved in ERK1/2 activation in our cellular model (Fig. 4B). Recent 
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evidence also suggests that β-arrestins can act as signal transduction scaffolds for ERK1/2 
activation following agonist-stimulated receptor internalization (Reiter and Lefkowitz, 2006). We 
thus examined if the use of dynasore, a small molecule GTPase inhibitor that targets dynamin and 
blocks endocytosis, could lead to a decrease in ERK1/2 phosphorylation (Fig. 4B). We did not 
observe significant changes in NT-induced ERK1/2 activation in the presence of dynasore, 
suggesting that NTS1-induced ERK1/2 phosphorylation is not dependent on β-arrestin 
internalization. 
We next investigated the contributions of the Gα13, Gαq and Gαi/o, proteins to the hNTS1-mediated 
activation of the ERK1/2 pathway. The involvement of Gα13 in ERK1/2 phosphorylation was 
determined by exposing the CHO-K1 cells expressing hNTS1 to a 30 min pretreatment with 10 
µM Y27632, a cell-permeable and highly selective inhibitor of Gα13-induced Rho-associated 
kinases (ROCK) activation (Narumiya et al., 2000). No significant differences in ERK1/2 
phosphorylation were detected following Y27632 pretreatment (Fig. 4B). We next used the 
UBOQIC blocker and the potent PKC inhibitor Gö6983 to evaluate the roles of Gαq protein and 
the subsequent downstream phospholipase Cb-DAG-PKC pathway, respectively, in ERK1/2 
activation. Both inhibitors were found to reduce the long-lasting effect of NT on ERK1/2 
phosphorylation, suggesting that hNTS1-induced ERK1/2 activation involves the sequential 
activation of Gαq and PKC (Fig. 4C). 
Finally, GPCRs are capable of inducing ERK1/2 activation via PTX-sensitive G proteins with Src 
kinase and Gβ/γ-dependent mechanisms	(Rozengurt, 2007). The contribution of Gαi/o protein to 
hNTS1-mediated ERK1/2 activation was therefore determined following an overnight 
pretreatment with PTX as a Gαi/o blocking agent. Despite the demonstration that hNTS1 triggered 
ERK1/2 activation through Gαq (Fig. 4C), a complete loss of ERK1/2 phosphorylation was 
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observed in PTX-treated cells (Fig. 4D), thus highlighting the key role for Gαi/o in NT-induced 
ERK1/2 activation. Since PTX pretreatment induces ADP-ribosylation of Gαi/o proteins and locks 
them into their inactive heterotrimeric conformation, we then evaluated whether Gαi/o-mediated 
ERK1/2 activation was induced by a Gβ/γ-dependent mechanism by treating cells with gallein, a 
Gβ/γ signaling inhibitor (Bonacci et al., 2006; Smrcka, 2013). No differences in the ERK1/2 
phosphorylation rate between gallein-treated and untreated cells were recorded, suggesting that 
NT-induced ERK1/2 activation is mediated by Gαi/o activity and not by Gβ/γ-mediated signaling 
(Fig. 4D). We finally tested whether Gαi/o-induced ERK1/2 activation was mediated through 
downstream activation of the proto-oncogene tyrosine-protein kinase c-Src. This non-receptor 
tyrosine kinase can be activated by Gαi/o and leads to ERK1/2 activation through direct 
phosphorylation of Ras/Raf or by indirect activation that involves EGFR transactivation (D. K. 
Luttrell and L. M. Luttrell, 2004; New and Wong, 2007; Piiper and Zeuzem, 2004). As shown in 
Fig. 4D, the inhibition of c-Src by a 30-min pretreatment with 1 µM PD166285, a non-selective 
c-Src and receptor tyrosine kinase inhibitor (Panek et al., 1997), resulted in a loss of more than 
75% of the ERK1/2 activation as well as in the appearance of a delay in the ERK1/2 
phosphorylation rate. Since we had previously demonstrated that ERK1/2 phosphorylation was 
independent of EGFR activation, the results obtained with PD166285 suggest that in our cellular 
model, hNTS1-mediated ERK1/2 activation may result from direct c-Src activation by Gαi/o. 
 
3.5 Whole-cell integrated responses following hNTS1 activation 
Because NTS1 activates several signaling pathways, we next used impedance-based cell 
monitoring approach to monitor and quantify the whole-cell integrated response resulting from the 
activation of hNTS1 with NT, NT (8-13) or NN. Impedance monitoring is a noninvasive label-free 
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technique that allows the real-time measurement of dynamic mass redistribution (DMR) in living 
cells grown on gold-plated electrodes and exposed to different ligands. As shown in Fig. 5 A-F, 
NT, NT(8-13), and NN produced a similar response profile over time, for each ligand 
concentration tested (i.e. 1, 10, 100, and 1000 nM), in which at least two distinct phases and one 
transient plateau could be observed. Immediately after the stimulation of CHO-hNTS1 cells, a 
rapid increase in the response signal was observed until it reached a transient maximum value 
followed by a plateau, which is only present for stimulations at 100 and 1000 nM. This maximum 
was then pursued by a slow decrease of the response until a return to the baseline at 180 min after 
stimulation. NT induced a more sustained response than NT(8-13) and NN at high concentrations 
(100 and 1000 nM) but the global shape of the curve was not affected (Fig. 5 C-D). As a control, 
L15 media was applied to CHO-hNTS1 cells, which did not produce any variations in the 
normalized response aside from the injection peak (Fig. 5E). As expected, the response of CHO-
hNTS1 cells stimulated with 10 µM of the NTS1 receptor antagonist SR48692 did not show any 
changes in the normalized response (Fig. 5G). A whole-cell integrated concentration-response 
curve was generated using the maximum value of the normalized response for each ligand and is 
shown in Fig. 5G. The cellular response induced by either NT, NT(8-13) or NN was comparable, 
even at non-saturating ligand concentrations and no significant differences were observed between 
the EC50 values of the whole-cell integrated response triggered by these three ligands (Table 2). 
To corroborate the results obtained using the impedance-based cell response, we next used cell-
based surface plasmon resonance (SPR) to monitor the whole-cell integrated response resulting 
from the activation of hNTS1 with 1 µM NT, NT (8-13) or NN. Like the impedance-based method, 
SPR is a noninvasive label-free technique that allows to quantify DMR in living cells grown on 
SPR substrate; however, this technique is based on an optical measurement instead of an electrical 
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measurement. As shown in Fig. 6 A-F, NT, NT(8-13), and NN produced an SPR response profile 
in which at least three distinct phases and two transient plateaus could be observed. As a control, 
NT was applied to CHO-K1 cells (Mock cells) (Fig. 6A) or L15 media was applied to CHO-
hNTS1 cells (Fig. 6B), which did not produce any variations in the SPR signal aside from the 
injection peak. Prior to stimulation, the SPR signal was stable, indicating a steady-state level of 
cellular activity. Immediately after the stimulation of CHO-hNTS1 cells, a rapid decline in the 
SPR signal was observed until it reached a transient minimum value (-6.8 ± 1.0 reflectance 
variation unit (RVU), -4.2 ± 1.0 RVU and -5.0 ± 1.2 RVU for NT, NT(8-13) and NN, respectively), 
which was identified as phase I. We next observed an increase in the SPR signal (phase II), which 
could be quantified by calculating the difference between the minimum and the first observed 
plateau when cell response progressed toward a transient stable state after stimulation (22.0 ± 1.2 
RVU for NT, 20.2 ± 2.1 RVU for NT(8-13) and 21.0 ± 0.8 RVU for NN). Following this first 
plateau, another increase was observed and was identified as phase III. This third phase was 
quantified by calculating the difference between the value at the first plateau and the value at the 
second plateau after stimulation (13.7 ± 2.8 RVU, 11.7 ± 3.1 RVU and 13.8 ± 1.3 RVU for NT, 
NT(8-13) and NN, respectively). No significant differences were observed between all phases of 
the SPR response (Fig. 6F). 
DMR quantification experiments (changes in cell monolayer impedance and SPR) thus revealed 
similar cellular behaviors in response to NT, NT(8-13) or NN stimulation, suggesting that the 
integrated signatures triggered by NTS1 activation lead to similar cellular responses. 
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4. Discussion 
 
In the present study, we report the signaling signature of the hNTS1 receptor in CHO-K1 cells 
following its activation by NT, NN, and NT(8-13) using BRET-based and label-free whole-cell 
DMR sensing assays (changes in cell monolayer impedance and SPR). The characterization of the 
hNTS1-mediated cellular signaling network revealed that NT, NT(8-13), and NN activate the Gαq-
, Gαi/o-, Gα13-, and Gαs-protein signaling pathways with similar efficacies and potencies. 
Furthermore, all ligands stimulated the production of inositol phosphate, modulated cAMP 
accumulation as well as activated ERK1/2 in our cellular model (See Fig. 7 for a comprehensive 
scheme of the signaling pathways activated by hNTS1). Nevertheless, we noticed that NN was less 
potent than NT and NT(8-13) for inducing the recruitment of β-arrestins, whereas NT(8-13) was 
more potent than NT and NN in activating the IP signaling pathway. Despite these distinct 
signaling profiles toward different effector systems, the integrated signatures revealed by two 
different label-free whole-cell DMR sensing assays (i.e. changes in cell monolayer impedance and 
SPR; Fig. 5 and Fig. 6) led to identical cellular responses by the three ligands. 
Interaction between hNTS1 and G proteins have been mainly based on the activation of second 
messenger signaling pathways and not on a direct assessment of the physical interactions between 
the receptor and the heterotrimeric G proteins. Our results reveal that hNTS1 stimulation promoted 
the engagement of different G protein families at the G protein level, which was previously 
demonstrated by their coupling to various downstream signaling pathways and by the use of signal 
transduction inhibitors (Pelaprat, 2006; Vincent et al., 1999; Z. Wu et al., 2012). We found that 
hNTS1 stimulation induced Gαq activation and the subsequent production of inositol phosphate. 
The Gαq-dependent pathway was confirmed by the application of the Gαq inhibitor UBOQIC. 
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These results are consistent with the previous findings in other cell types, which show that NTS1, 
via its coupling to the Gαq subunit, mediates the activation of phospholipase C and the production 
of IP and diacylglycerol, leading to the mobilization of intracellular calcium and activation of PKC 
in both neuronal and non-neuronal cell types (Amar et al., 1987; Choi et al., 1999; Najimi et al., 
2002; Oury-Donat et al., 1995; Schaeffer et al., 1995; Skrzydelski et al., 2003; Snider et al., 1986; 
Wang and T. Wu, 1996).  
NTS1-induced Gαi/o activation was previously suggested by experimental studies that showed the 
PTX-dependent sensitivity of [35S]-GTPγS binding following NT activation (Gailly et al., 2000) 
and by inhibiting cAMP production in N1E115 cells (Bozou et al., 1986; Oury-Donat et al., 1995). 
Reports have also shown that NT stimulated cAMP production in heterologous cells expressing 
human or rat NTS1 as well as in pancreatic cancer cells endogenously expressing hNTS1, 
indicating that NTS1 also couples to Gαs (Ishizuka et al., 1993; Richard et al., 2001; Sarret et al., 
2010; Skrzydelski et al., 2003; Yamada et al., 1993). Here, our results provide a new insight into 
the discrepancy that demonstrated both Gαi/o- and Gαs-NTS1 coupling (Fig. 2). Indeed, we 
demonstrate that NT-induced cAMP production was increased in the presence of PTX. Since Gαs 
and Gαi/o regulate the same intracellular effector, these results suggest that in this host cell system, 
hNTS1 is preferentially coupled to adenylyl cyclase through Gαs rather than Gαi/o, consequently 
leading to cAMP production. It has also been suggested that NTS1 causes an increase in the 
cellular level of cAMP through the Gαq/11-mediated activation of calcium-dependent adenylyl 
cyclase in PC3 cancer cells (Carraway and Mitra, 1998). Here, we found that the Gαq blocker 
UBOQIC did not affect NT-induced cAMP accumulation. These data thus reinforce the central 
role played by Gαs in cAMP production. 
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We also demonstrate the ability of NTS1 to engage Gα13 (Fig. 1). This finding is in line with reports 
showing that NT modulates the activity of small Rho GTPases, such as Cdc42 and Rac1, 
downstream of Gα13 in U373 glioblastoma cells (Servotte et al., 2006). These results further 
suggest that NTS1 activation could mediate cytoskeletal rearrangements and lead to the emergence 
of stress fibers and cell migration (Moura et al., 2013). 
β-Arrestins bind agonist-activated receptors and play a central role in mediating GPCR 
desensitization and internalization (Ferguson, 2001; Pierce and Lefkowitz, 2001). We therefore 
investigated the effects of hNTS1 stimulation on G protein-independent signaling by monitoring 
the recruitment β-arrestins 1 and 2 to the receptor (Fig. 3). Our results of hNTS1-triggered β-
arrestin recruitment indicate rapid binding of both β-arrestins to the receptor when subnanomolar 
levels of ligands are used. The cellular trafficking of β-arrestins is differentially regulated via their 
association to distinct GPCR subtypes; class A receptors interact with β-arrestin 2 with higher 
affinities than β-arrestin 1, while class B receptors bind both β-arrestins with similarly high 
affinities (Drake et al., 2006). This type of β-arrestin-receptor interaction appears to determine 
receptor fate; GPCRs that are tightly bound to β-arrestins (class B) are more frequently targeted to 
lysosomal compartments where they undergo proteolytic degradation, whereas receptors 
dissociating rapidly from β-arrestins (class A) are recycled back to the plasma membrane (Drake 
et al., 2006). Our results support the classification of hNTS1 as a class B GPCR (Oakley et al., 
2001; 2000; Zhang, 1999) and are consistent with previous observations demonstrating that hNTS1 
receptors are trafficked to lysosomal compartments for degradation (Vandenbulcke et al., 2000). 
Our results also reveal that both NT and NT(8-13) were more potent in inducing the recruitment 
of β-arrestins compared to NN. These differences might be driven by the presence of GRK kinases, 
which have been shown to influence GPCR signaling and trafficking (Liggett, 2011). Accordingly, 
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Inagaki et al. (2015) recently reported that GRK2 and GRK5 differentially phosphorylate the 
NTS1 receptor. Phosphorylation of NTS1 by GRK2 is agonist-independent and occurs only on the 
C-terminal Ser residues, whereas phosphorylation of NTS1 by GRK5 is agonist-dependent and 
requires the phosphorylation of the Ser and Thr residues located in intracellular loop 3 and the C-
terminus. Since these GPCR kinases seem to be endogenously expressed in CHO-K1 cells (Osorio-
Espinoza et al., 2014), we can therefore speculate that they could affect the responses induced by 
the different NT agonists and lead to different profiles of β-arrestin recruitment.  
NTS1 was found to be overexpressed in several cancer cell lines (Mustain et al., 2011), such as 
colonic adenocarcinomas (Evers, 2006; Müller et al., 2011; Yoshinaga et al., 1992; Zhao et al., 
2007), breast (Dupouy et al., 2009; Souazé et al., 2006), and lung cancers (Allen et al., 1988; Bunn 
et al., 1992; Davis et al., 1991). Thus, we were also interested in investigating whether NTS1 
signaling by NT, NT(8-13), and NN led to activation of the MAPK proliferative pathway. Since 
many signaling pathways, including G protein-dependent and G protein-independent pathways, 
lead to ERK1/2 phosphorylation, the pharmacological inhibitors of upstream signaling molecules 
were used to decipher the contribution of the various effectors involved (Fig. 4). In contrast to 
previous studies demonstrating that the EGFR inhibitor gefitinib inhibited NT-induced ERK1/2 
phosphorylation in colonic HT-29 and prostatic PC3 cancer cell lines (Hassan et al., 2004; Müller 
et al., 2011), we did not observe that EGFR transactivation was required for ERK1/2 activation. 
These discrepancies may be related to the fact that the cancer cell lines express the third member 
of the NT receptor family NTS3 (Morinville et al., 2004; Sarret et al., 2001). Indeed, as observed 
by (Martin et al., 2002), co-expression of NTS3 with NTS1 significantly affects NT-dependent 
intracellular signaling, such as ERK1/2 phosphorylation. Our results also reveal that ERK1/2 
activation does not involve Gα13 recruitment since the highly selective ROCK inhibitor Y27632 
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did not induce any changes in ERK1/2 phosphorylation. Several lines of evidence suggest that in 
addition to their role in desensitization/internalization, β-arrestins act as signal transduction 
scaffolds for ERK1/2 activation following agonist-stimulated receptor internalization (Pierce and 
Lefkowitz, 2001). Since hNTS1 internalizes via clathrin-coated pits and through a dynamin-
dependent mechanism (Savdie et al., 2006; Vandenbulcke et al., 2000; Vincent et al., 1998), we 
further examined if dynasore that interferes with the GTPase activity of dynamin and blocks 
receptor endocytosis exerted an inhibitory action on ERK1/2 activation. No significant changes in 
NT-induced ERK1/2 phosphorylation were observed in the presence of dynasore, thus suggesting 
that hNTS1-mediated ERK1/2 activation occurs independent of hNTS1 internalization and of β-
arrestin signaling in this cell type. 
Depending on the receptor and cell type, ERK1/2 activation may be mediated by PTX-sensitive or 
PTX-insensitive G proteins. We demonstrate here that Gαq inactivation by the UBOQIC blocker 
or inhibition of the downstream PKC by Gö6983 partially blocked ERK1/2 phosphorylation. These 
results thus support the involvement of the PTX-insensitive Gαq-PLCb-DAG-PKC pathway in 
hNTS1-induced ERK1/2 activation. This finding is in agreement with previous findings showing 
that NT stimulates ERK1/2 phosphorylation through a PKC-Raf-1-dependent signaling pathway 
(Guha et al., 2003). Our results also reveal the key role played by Gαi/o in hNTS1-mediated 
ERK1/2 phosphorylation. Indeed, locking Gαi/o in its inactive conformation by PTX pretreatment 
led to a complete loss of ERK1/2 phosphorylation. This PTX-sensitive effect of ERK1/2 activation 
is Gαi/o dependent since the Gβ/γ inhibitor gallein does not affect the ERK1/2 phosphorylation 
induced by NT. These data are consistent with other studies reporting that NT stimulates the 
transcription of the immediate-early gene Krox-24, a target of the ERK1/2 pathway, through a 
PTX-sensitive pathway (Poinot-Chazel et al., 1996). 
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The most unexpected result found here is that Gαi/o inhibition by PTX completely prevents hNTS1-
induced ERK1/2 phosphorylation (Fig. 4). This finding is indeed surprising since we have 
demonstrated that ERK1/2 activation is also regulated in a Gαq-PLCb-DAG-PKC-dependent 
manner. This result may be explained by the fact that PTX, which blocks the Gαi/o-mediated 
inhibition of adenylyl cyclase thereby promoting cAMP production, would inhibit the activation 
of Raf-1 (Piiper et al., 2000). Raf-1 inhibition would reduce the hNTS1-induced ERK 
phosphorylation through the PTX-insensitive Gαq-PLCb-DAG-PKC pathway (Fig. 7). This 
hypothesis is supported by our demonstration that inactivation of Gαi/o by PTX increases the 
intracellular cAMP level in CHO-hNTS1 cells in response to NT (Fig. 2). Furthermore, the 
absence of complete inhibition of ERK1/2 activation using the c-Src inhibitor PD166285 further 
reinforces the involvement of the PTX-insensitive Gαq-PLCb-DAG-PKC-Raf-1-dependent 
pathway in ERK1/2 activation. We can thus conclude that the full activation of ERK1/2 in CHO-
hNTS1 cells by NT requires signaling through both a PTX-sensitive Gαi/o-c-Src signaling pathway 
and a PLCb-DAG-PKC-Raf-1-dependent pathway downstream of Gαq (Fig. 7). 
Altogether, our results demonstrate the functional coupling of agonist-stimulated hNTS1 to the G 
proteins Gαq, Gαi1, GαoA, and Gα13 as well as its ability to recruit β-arrestins and activate the IP1, 
cAMP, and ERK1/2 second messenger signaling cascades. The BRET-based and label-free whole-
cell sensing tools used here to decipher the NTS1 signaling signature may also be helpful in 
accelerating the validation of potential NTS1 biased ligands. Biased signaling of GPCRs is of 
growing interest to drug discovery, particularly in the quest to identify compounds with high 
therapeutic potential while reducing unwanted side effects (Correll and McKittrick, 2014; Garland, 
2013; Kenakin, 2012). Our study will form the basis for the future development of therapeutics 
targeting hNTS1 in clinical indications such as pain management.
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Figures 
 
Fig. 1. hNTS1 promotes the engagement of G proteins Gαq, Gαi1, GαoA, and Gα13 in CHO-
K1 cells. Effect of increasing concentrations of NT, NT(8-13), or NN on the dissociation of Gαq 
(A), Gαi1 (B), GαoA (C), and Gα13 (D). BRET was measured 10 min after the addition of the 
ligands. Each data set represents the mean of three independent experiments, which were each 
done in triplicate, and is expressed as the mean ± S.E.M.. 
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Fig. 2. Downstream G protein signaling reveal functional coupling with Gαq, Gαs, and Gαi/o. 
(A) Effect of increasing concentrations of NT, NT(8-13), or NN on IP1 production. (B) Effect of 
pretreatment with the Gαq inhibitor UBOQIC (1 µM for 30 min) on IP1 accumulation following 
stimulation with 1 µM NT. (C) Effect of increasing concentrations of NT, NT(8-13), or NN on 
cAMP production. (D) Effect of pre-treatment with UBOQIC (1 µM for 30 min) or Pertussis toxin 
(PTX; 100 ng/ml, overnight) on cAMP accumulation following stimulation with 1 µM NT. * P < 
0.05 in the Mann-Whitney test compared to the activation levels without UBOQIC or PTX 
treatment. Each data set represents the mean of three independent experiments, which were each 
performed in triplicate, and is expressed as the mean ± S.E.M.. 
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Fig. 3. NTS1 activation leads to the recruitment of β-arrestins 1 and 2. Kinetics of β-arrestin 
1 (A) and β-arrestin 2 (B) recruitment following NTS1 activation. The black open circles represent 
the BRET ratio of cells stimulated only with buffer. Concentration-response curves of NT, NT(8-
13), or NN on the recruitment of β-arrestin 1 (C) or β-arrestin 2 (D). Each data set represents the 
mean of three independent experiments, which were each done in triplicate, and expressed as the 
mean ± S.E.M.. 
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Fig. 4. NTS1 activates ERK1/2 by a Gαi/o-dependent mechanism. (A) Effect of increasing 
concentrations of NT, NT(8-13), or NN on ERK1/2 phosphorylation. (B-D) Effects of pretreatment 
on ERK1/2 phosphorylation kinetics induced by 1 µM NT. (B) Pre-treatment with the EGFR 
inhibitor PD168393 (250 nM for 30 min), ROCK inhibitor Y27632 (10 µM for 30 min) or 
endocytosis inhibitor dynasore (80 µM for 30 min). (C) Pre-treatment with the Gαq blocker, 
UBOQIC (1 µM for 30 min) or PKC inhibitor Gö6983 (1 µM for 30 min). (D) Pre-treatment with 
pertussis toxin (PTX; 100 ng/ml, overnight), Gβ/γ-signaling inhibitor gallein (20 µM for 30 min) 
or c-Src inhibitor PD166285 (1 µM for 30 min). Each data set represents the mean of four 
independent experiments, which were each performed in duplicate, and is expressed as the mean 
± S.E.M.. 
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Fig. 5. Effect of NTS1 activation on the resistivity of a cell monolayer. (A-F) Dynamic mass 
redistribution kinetics assessed by cell monolayer impedance. (A-D) Normalized response of 
CHO-hNTS1 cells stimulated with (A) 1 nM, (B) 10 nM, (C) 100nM, and (D) 1000 nM of NT 
(blue line), NT(8-13) (red line), or NN (green line). (E) Normalized response of CHO-hNTS1 cells 
stimulated with L15 medium. (F) Normalized response of CHO-hNTS1 cells stimulated with 10 
µM of the NTS1 antagonist SR48692. (G) Effect of increasing concentrations of NT, NT(8-13), 
or NN on the whole-cell integrated response. The arrows on each graph represent the injection 
time of the compound. The dotted lines represent the S.E.M. values. Each data set represents the 
mean of three independent experiments, which were each performed in duplicate, and is expressed 
as the mean ± S.E.M..  
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Fig. 6. Effect of NTS1 activation on the whole-cell integrated response monitored by SPR. 
(A-F) Dynamic mass redistribution kinetics assessed by SPR. (A) Reflectance variation of CHO-
K1 stimulated with NT (1 µM). Reflectance variation of CHO-hNTS1 stimulated with (B) L15 
medium, (C) NT (1 µM), (D) NT(8-13) (1 µM) and (E) NN (1 µM). The arrows on each graph 
represent the injection time of the compound. The gray dotted lines represent the S.E.M. values. 
(F) Reflectance variation in the RVU of phases I, II and III for each agonist. No significant 
differences were found between NT and NT(8-13) or NN on the Kruskal-Wallis test followed by 
Dunn’s post hoc test. Each data set represents the mean of 6-8 independent experiments and is 
expressed as the mean ± S.E.M.. 
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Fig. 7. Proposed signaling signature of hNTS1 following activation by NT, NT(8-13), or NN. 
Following its activation by either NT, NT(8-13), or NN, hNTS1 functionally couples to Gαq, Gα13, 
Gαi/o, and Gαs and promotes the recruitment of β-arrestins 1 and 2. Furthermore, we demonstrated 
that in our cellular model, NTS1 was able to induce ERK1/2 phosphorylation via Gαq- and Gαi/o-
dependent mechanisms. Our results showed that Gαq-dependent signaling is involved in the late 
ERK1/2 response, whereas Gαi/o signaling via c-Src is responsible for the rapid increase in ERK1/2 
phosphorylation. The stimulatory pathways are shown by the green arrows, and the red-squared 
arrows represent the inhibitory pathways and the inhibitors used in this study. 
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Table 1: Peptide sequence of NT, NT(8-13) and NN 
Compound Sequence 
Neurotensin  pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-COOH 
Neurotensin (8-13)  H2N- Arg-Arg-Pro-Tyr-Ile-Leu-COOH 
Neuromedin N  H2N- Lys-Ile-Pro-Tyr-Ile-Leu-COOH 	
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Table 2: EC50 values for NT, NT(8-13) and NN on hNTS1 activated signaling pathways 
 
Pathway 
EC50, nM 
Neurotensin,NT Neurotensin 8-13, NT(8-13) Neuromedin N, NN 
Gαq 1.84 ± 0.29 1.92 ± 0.32 1.89 ± 0.34 
Gαi1 5.83 ± 6.32 2.36 ± 3.40 6.64 ± 8.43 
GαoA 3.44 ± 1.26 4.12 ± 1.56 3.37 ± 1.37 
Gα13 3.78 ± 1.37 3.01 ± 1.36 4.62 ± 2.54 
IP1 0.33 ± 0.05 2.27 ± 0.34b 0.86 ± 0.16a, c 
cAMP 1.32 ± 0.28 0.79 ± 0.22 1.54 ± 0.42 
β-arr-1 1.60 ± 0.29 2.01 ± 0.18 5.41 ± 1.03b, d 
β-arr-2 0.28 ± 0.09 0.74 ± 0.18 2.01 ± 0.67b, c 
pERK1/2 1.10 ± 0.13 0.60 ± 0.14 1.09 ± 0.25 
DMR 10.1 ± 7.17 3.10 ± 1.81 4.67 ± 3.65 
 
a P<0.05; b P<0.01 compared to NT and c P<0.05; d P<0.01 compared to NT(8-13); Kruskal-Wallis followed by a 
Dunn’s post hoc test. 	
 
